SAVA - Cassava Alzheimer's candidate simufilam clears phase 3 safety review
2024-03-25 11:58:56 ET
More on Cassava Sciences
- Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go?
- Cassava Sciences And Alzheimer's Disease: Opaque Clarity
- Biotech And Pharma Diversification Pays Off
- Cassava Sciences again under scrutiny over Alzheimer's drug research
- Seeking Alpha’s Quant Rating on Cassava Sciences